MOTS-c and humanin are both mitochondrial-derived peptides — small peptides encoded within mitochondrial DNA — and both are studied in the context of aging and metabolic health. They differ in emphasis: MOTS-c is studied more for metabolism and exercise-mimetic effects, humanin more for cytoprotection and neuroprotection. Both are preclinical research compounds.
At a glance
| MOTS-c | Humanin | |
|---|---|---|
| Type | Mitochondrial-derived peptide | Mitochondrial-derived peptide |
| Studied for | Metabolism, insulin sensitivity, exercise-mimetic | Cytoprotection, neuroprotection |
| Evidence | Largely preclinical (cell/animal) | Largely preclinical (cell/animal) |
| FDA status | Not approved (research chemical) | Not approved (research chemical) |
| Human data | Limited | Limited |
The bottom line
Bottom line: Two members of the same intriguing family — peptides encoded by mitochondrial DNA — with different research emphases. MOTS-c leans metabolic/exercise-mimetic; humanin leans protective and neuroprotective. Both are early-stage, unapproved, and supported mainly by cell and animal work; human longevity claims are not established.
Frequently asked questions
What are mitochondrial-derived peptides?
They are small peptides encoded within mitochondrial DNA, such as MOTS-c and humanin, studied for roles in metabolism, stress resistance, and aging. The research is largely preclinical.
What's the difference between MOTS-c and humanin?
MOTS-c is studied more for metabolic and exercise-mimetic effects, while humanin is studied more for cytoprotective and neuroprotective roles. Both are unapproved research compounds.
Do they slow aging in humans?
No peptide has been shown to slow human aging in rigorous trials. MOTS-c and humanin are intriguing in cell and animal studies, but human evidence is limited and longevity claims are not established.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. Peer-reviewed study
- Lee C, Kim KH, Cohen P. MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016. Peer-reviewed study
- Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne). 2023. Peer-reviewed study
- Kong BS, Lee C, Cho YM. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. Diabetes Metab J. 2023. Peer-reviewed study
- Yin Y, Li Y, Ma B, et al. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. Adv Sci (Weinh). 2024. Peer-reviewed study
- Yin Y, Pan Y, He J, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacol Res. 2022. Peer-reviewed study
- Yen K, Mehta HH, Kim SJ, et al. The mitochondrial-derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020. Peer-reviewed study
- Hashimoto Y, Niikura T, Tajima H, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci U S A. 2001. Peer-reviewed study
- Lei H, Rao M. The role of humanin in the regulation of reproduction. Biochim Biophys Acta Gen Subj. 2022. Peer-reviewed study
- Coradduzza D, Congiargiu A, Chen Z, et al. Humanin and Its Pathophysiological Roles in Aging: A Systematic Review. Biology (Basel). 2023. Peer-reviewed study
- Niikura T. Humanin and Alzheimer's disease: The beginning of a new field. Biochim Biophys Acta Gen Subj. 2022. Peer-reviewed study
- Xiao J, Kim SJ, Cohen P, et al. Humanin: Functional Interfaces with IGF-I. Growth Horm IGF Res. 2016. Peer-reviewed study